Vanda Pharmaceuticals (VNDA) Research & Development (2010 - 2026)

Vanda Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $28.4 million in Q1 2026.

• Quarterly Research & Development fell 20.38% year-over-year to $28.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (down 92.0% YoY) and the FY2025 annual result came in at $14.4 million, down 80.65% from the prior year.
• Research & Development improved to $28.4 million in Q1 2026 per VNDA's latest filing, from -$65.9 million in the prior quarter.
• Over five years, Research & Development peaked at $35.7 million in Q1 2025 and troughed at -$65.9 million in Q4 2025.
• A 5-year average of $16.5 million and a median of $21.0 million in 2022 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 68.82% in 2025, down 431.98% in 2025.
• Over 5 years, Research & Development stood at $18.5 million in 2022, then jumped by 31.89% to $24.3 million in 2023, then retreated by 18.48% to $19.8 million in 2024, then sank by 431.98% to -$65.9 million in 2025, then soared by 143.17% to $28.4 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $28.4 million, -$65.9 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.